Although previous elegant experimental studies showed the efficacy of GT to correct some phenotypic signs of RPS19 deficiency, there is a lack of preclinical evidence demonstrating the safety and efficacy of clinically applicable vectors in HSCs from patients with DBA. This evidence concerns the gene RPS19 and Diamond-Blackfan anemia.